16.12.2025, 15:30
Weihnachtliche Führung durch die einzigartige Sammlung historischer Mikroskope auf dem Campus Berlin-Buch
Lernen Sie die Anfänge der Berliner Mikroskop-Produktion und ihren Einfluss auf die moderne Biomedizin kennen - unter anderem auf die medizinische Forschung in Berlin-Buch!
more ...
16.12.2025, 16:30
Invitation: Christmas tour of the unique collection of historical microscopes on the Campus Berlin-Buch
Discover the beginnings of Berlin’s microscope production and its influence on modern biomedicine. Neuroscientist Prof. Dr. Helmut Kettenmann will guide you through the microscope exhibition at the Ma...
more ...
06.01.2026, 16:00
Vorlesung und Lehrerfortbildung: "Wenn das Immunsystem das Gehirn angreift – Autoimmunerkrankungen des zentralen Nervensystems"
Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch. Für Lehrkräfte, Schülerinnen und Schüler sowie Interessierte.
more ...
T-knife Therapeutics is one of the most successful start-ups in the biotech scene. Founded in 2018 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) with the support of Charité – Universitätsmedizin Berlin, its mission is to develop therapies that can combat cancer with the help of patients’ immune systems. Over the course of many years, the research team led by Professor Thomas Blankenstein has worked towards genetically modifying human T cells in such a way that their receptors can target and destroy specific tumor cells. Using this unique technology, the first T-cell receptor gene therapy in Germany is now being tested in a clinical trial.
The prospect that the first clinical trials will lead to the successful treatment of patients inspires and motivates the team of OMEICOS Therapeutics GmbH. All previous data suggest that the scientists and founders have for the first time found a
